SARAFEM Drug Patent Profile
✉ Email this page to a colleague
When do Sarafem patents expire, and what generic alternatives are available?
Sarafem is a drug marketed by Eli Lilly And Co and Apil and is included in two NDAs.
The generic ingredient in SARAFEM is fluoxetine hydrochloride. There are twenty-seven drug master file entries for this compound. Seventy-one suppliers are listed for this compound. Additional details are available on the fluoxetine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sarafem
A generic version of SARAFEM was approved as fluoxetine hydrochloride by APNAR PHARMA LP on August 2nd, 2001.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SARAFEM?
- What are the global sales for SARAFEM?
- What is Average Wholesale Price for SARAFEM?
Summary for SARAFEM
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 174 |
Clinical Trials: | 10 |
Patent Applications: | 4,661 |
Drug Prices: | Drug price information for SARAFEM |
What excipients (inactive ingredients) are in SARAFEM? | SARAFEM excipients list |
DailyMed Link: | SARAFEM at DailyMed |
Recent Clinical Trials for SARAFEM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Bogachan Sahin | Phase 2 |
Torrent Pharmaceuticals Limited | Phase 1 |
Eli Lilly and Company | Phase 3 |
Pharmacology for SARAFEM
Drug Class | Serotonin Reuptake Inhibitor |
Mechanism of Action | Serotonin Uptake Inhibitors |
US Patents and Regulatory Information for SARAFEM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly And Co | SARAFEM | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-007 | Jul 6, 2000 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Apil | SARAFEM | fluoxetine hydrochloride | TABLET;ORAL | 021860-002 | May 19, 2006 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Eli Lilly And Co | SARAFEM | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-008 | Jul 6, 2000 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Apil | SARAFEM | fluoxetine hydrochloride | TABLET;ORAL | 021860-001 | May 19, 2006 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SARAFEM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Eli Lilly And Co | SARAFEM | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-007 | Jul 6, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Eli Lilly And Co | SARAFEM | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-008 | Jul 6, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Eli Lilly And Co | SARAFEM | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-008 | Jul 6, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Eli Lilly And Co | SARAFEM | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-008 | Jul 6, 2000 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SARAFEM
See the table below for patents covering SARAFEM around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Indonesia | 26861 | ⤷ Sign Up | |
Australia | 7683674 | ⤷ Sign Up | |
South Africa | 8601212 | ⤷ Sign Up | |
European Patent Office | 0193355 | ANALGESIC COMPOSITION | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |